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bone resorption, and increase bonemass in both animals and humans. To obtain insight into the temporal cellular
and transcriptional changes in the osteoblast (OB) lineage associatedwith long-term Scl-Ab treatment, stereolog-
ical and transcriptional analyses of the OB lineage were performed on lumbar vertebrae from aged ovariecto-
mized rats. Animals were administered Scl-Ab 3 or 50 mg/kg/wk or vehicle (VEH) for up to 26 weeks (d183),
followed by a treatment-free period (TFP). At 50 mg/kg/wk, bone volume (BV/total volume [TV]) increased
through d183 and declined during the TFP. Bone formation rate (BFR/bone surface [BS]) and total OB number
increased through d29, then progressively declined, coincident with a decrease in total osteoprogenitor (OP)
numbers from d29 through d183. Analysis of differentially expressed genes (DEGs) from microarray analysis
of mRNA isolated from laser capture microdissection samples enriched for OB, lining cells, and osteocytes
(OCy) revealedmodules of genes that correlated with BFR/BS, BV/TV, and osteoblastic surface (Ob.S)/BS. Expres-
sion change of canonical Wnt target genes was similar in all three cell types at d8, including upregulation of
Twist1 andWisp1. At d29, the pattern of Wnt target gene expression changed in the OCy, with Twist1 returning
to VEH level, sustained upregulation of Wisp1, and upregulation of several other Wnt targets that continued
into the TFP. Predicted activation of pathways recognized to integrate with and regulate canonical Wnt signaling
were also activated at d29 in the OCy. The most signiﬁcantly affected pathways represented transcription factor
signaling known to inhibit cell cycle progression (notably p53) andmitogenesis (notably c-Myc). These changes
occurred at the time of peak BFR/BS and continued as BFR/BS declined during treatment, then trended toward
VEH level in the TFP. Concurrent with this transcriptional switch was a reduction in OP numbers, an effect that
would ultimately limit bone formation. This study conﬁrms that the initial transcriptional response in response
to Scl-Ab is activation of canonical Wnt signaling and the data demonstrate that there is induction of additional
regulatory pathways in OCy with long-term treatment. The interactions between Wnt and p53/c-Myc signaling
may be key in limiting OP populations, thus contributing to self-regulation of bone formationwith continued Scl-
Ab administration.
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Sclerostin is a secreted protein of the osteocyte (OCy) and an inhib-
itor of bone formation [1]. The effects of sclerostin on bone metabolism
are based on its actions as an extracellular inhibitor of the canonicalWnt
signaling pathway, resulting in decreased bone formation and increased
bone resorption [2,3]. Inhibition of sclerostin with sclerostin antibody
(Scl-Ab) has been shown to stimulate bone formation, decrease bone
resorption, and increase bone mass in both animals and humans [4,5].
The rapid increases in bone formation with Scl-Ab have been acutely
associated with the activation of bone lining cells (LC) to form new
bone [6].
In contrast to acute Scl-Ab administration, which stimulates bone
formation on trabecular, endocortical, and periosteal surfaces, long-
term Scl-Ab administration exhibits a time-speciﬁc proﬁle of osteoblast
(OB) stimulation. In aged ovariectomized (OVX) rats, Li et al. [7] showed
self-regulation of bone formation in vertebral cancellous bone. Bone
formation rate per bone surface (BFR/BS) returned toward control
values after 6 months of continuous Scl-Ab administration, while de-
creases in bone resorption were sustained through month 6. In young
rats administered Scl-Ab, self-regulation of vertebral BFR/BSwas associ-
ated with reductions in osteoprogenitor (OP) populations [8]. These
histomorphometry data align with similar phenomena observed with
serum biomarkers in rats [9] and humans [10], where early increases
in serum bone formation markers with Scl-Ab were followed by
attenuation of this response over continuous treatment periods of 6–
12 months. Human studies also showed that bone resorption markers
were consistently decreased over a 12-month Scl-Ab treatment period.
Associatedwith the early activation of bone formation in response to
Scl-Ab treatment, the acute downstream signaling in vivo has been
shown to involve upregulation of selected canonical Wnt target genes
coincident with upregulation of extracellularmatrix genes in all mature
OB subpopulations, i.e., OB, LC, andOCy after enrichmentwith laser cap-
ture microdissection (LCM) [6]. It is unknown how the transcriptional
proﬁle changes with long-term treatment with Scl-Ab, or whether
there is a relationship between transcriptional changes and quantitative
changes in BFR/BS and the OB lineage. To investigate these potential
relationships, we utilized LCM-enriched subpopulations of the ma-
ture OB lineage to study the temporal transcriptional responses of
mature OB lineage to long-term Scl-Ab treatment and examined
the association of these responses with changes in bone formation
and resorption by histomorphometry and OB and OP numbers by
stereological methods.
2. Material and methods
2.1. Study design
Six-month-old Sprague–Dawley female rats (SD®IGS; Charles River
Laboratories, Hollister, CA) were OVX and left untreated for 8 weeks,
at which time they weighed approximately 400 g. Rats were assigned
to three treatment groups in a manner to achieve body weight balance
across treatment groups. Rats were administered by s.c. injection vehi-
cle (VEH); or 3 or 50 mg/kg/wk of a Scl-Ab (Scl-AbVI) once weekly up
to day (d)183 (Suppl Fig. 1). Scl-AbVI was engineered to be less immu-
nogenic in rats (rat Fc construct) than humanized antibody. The
50 mg/kg/wk Scl-Ab dose, which matches the high dose used in a rat
lifetime pharmacology study, provided an approximate 18-fold margin
to clinical exposure; the 3 mg/kg/wk dose approximated clinical expo-
sure (Amgen internal data). Up to 15 rats per group were euthanized
at d8, 29, 85, and 183. To assess effects following treatment with-
drawal, additional groups were maintained through a treatment-
free period (TFP) and euthanized at d197 and 267 for VEH and
3 mg/kg groups, and at d237 and 309 for VEH and 50 mg/kg groups.
For euthanasia, animals were anesthetized with isoﬂurane/oxygen
and then exsanguinated.To label active bone-forming surfaces for dynamic histomorphometry
and to facilitate OB and LC enrichment during LCM as described by Nioi
et al. [6], 10 mg/kg calcein green (in 2% sodium bicarbonate in saline)
was administered s.c. 13 and 3 days prior to scheduled euthanasia. At
necropsy, the ﬁrst and second lumbar vertebral (L1 and L2) bodies
were isolated for histomorphometry and peripheral quantitative com-
puted tomography (pQCT) analyses, respectively. At 4 °C, L6 body was
ﬁxed in 4% paraformaldehyde for 48 h then decalciﬁed in 10% EDTA
with 2% paraformaldehyde, processed to parafﬁn for stereological analy-
ses. L3 body was isolated and embedded in Tissue-Tek® O.C.T. (Sakura
Finetek, Torrance, CA) in Peel-A-Way® disposable histology molds
(Ted Pella, Inc., Redding, CA), snap frozen in liquid nitrogen, and stored
at−80 °C until sectioning.
Animals were cared for in accordancewith theGuide for the Care and
Use of Laboratory Animals, 8th Edition [11]. All research protocols were
approved by the Institutional Animal Care and Use Committee. Animals
were group-housed (two per cage) at an Association for Assessment
and Accreditation of Laboratory Animal Care, international-accredited
facility in nonsterile, ventilated, microisolator housing with corn cob
bedding. Animals had ad libitum access to pelleted feed (Rodent Diet
2020X, TekladDiets,Madison,WI) andwater (reverse osmosis puriﬁed)
using an automatic watering system. Animals were maintained on
a 12:12 h light:dark cycle in rooms with controlled temperature
(72 °F ± 2 °F) and humidity (30%–70%), and access to enrichment
opportunities (Nylabones and Rat Retreats or Rat Tunnels). Further
details on study design and animal care are provided in Supplemental
Material 1.
2.2. Histomorphometry and pQCT
L1 vertebral bodies were ﬁxed in 10% neutral buffered formalin
for 72 h and processed undecalciﬁed in methyl methacrylate for
histomorphometry. Undecalciﬁed stained and unstained sections of L1
were prepared and evaluated for static and dynamic histomorphometry
as described previously [12]. L2 vertebral bodies were scanned and
analyzed on a Stratec XCT Research M instrument (Norland Medical
Systems, Fort Atkinson, WI, software version 5.40). Additional de-
tails on histomorphometry and pQCT are provided in Supplemental
Material 1.
2.3. Stereological analyses of OB subpopulations
Vertebrae L6 from animals at d8, 29, and 183, of the dosing phase,
and d267 and 309, the last TFP time point for 3 and 50mg/kg, respec-
tively, were used for estimation of total number of subpopulations of
the Ob lineage. Due to small group size of d267 controls, three VEH
animals from d237 were combined with d267 VEH to increase the
group size. The stereological estimator, the physical fractionator
[13], was used to provide estimates of total number of cell subpopu-
lations (OB and OP) contained within the entire vertebral body.
Number estimates by these methods are independent of size, shape,
distribution, or orientation. The physical fractionator uses physical
disectors (i.e., paired consecutive thin sections that constitute a three-
dimensional [3-D] probe [volume] in which cells are counted). The
disector counting principle uses a unique counting feature of the cell,
in this case the nucleus, and a cell is only counted when the nucleus is
present in a sampled ﬁeld in one section of the disector (counting
ﬁeld) and not the other (lookup ﬁeld) [14]. A combination of immuno-
phenotyping, morphology, and location was used to classify cells for
estimation. Sets of disector sections were stained for runt-related tran-
scription factor 2 (Runx2) to identify subpopulations of OP, including
peritrabecular OP (PTb.OP) and marrow OP (Ma.Op) in cancellous
bone. PTb.Op were identiﬁed as Runx2-positive spindle-shaped cells
located typically one cell layer from the bone surface, frequently in
the canopy overlying Ob. Ma.Op were identiﬁed as a Runx2-positive
cell with a round to ovoid nucleus associated with thin-walled vessels
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positive populations would be consistent with an early (Ma.OP) and
late (PTb.OP) progenitor. Total OB number (Ob.N) was estimated from
sets for disector sections stained for osteonectin. OBs active in matrix
synthesis were identiﬁed as osteonectin-positive cells with oval nuclei
and variable amounts of cytoplasm depending upon the age of the
formative site interfaced with the bone surface (Suppl Fig. 2B). This
morphological classiﬁcation of the OB provided strong correlation of
mineralizing surface (MS/BS) with osteoblastic surface (Ob.S) estimat-
ed from the osteonectin-stained sections (Suppl Fig. 3). Further details
of immunohistochemical and stereological methods are provided in
Supplemental Material 1.
For statistical analysis, a two-way ANOVA was performed across all
three treatments for the treatment period data, with a Dunnett's post-
hoc test for comparisons with VEH (GraphPad Prism® v.6.05). During
the TFP, two-tailed t-tests were performed in Excel®. Signiﬁcance was
set to the level of p b 0.05.
2.4. LCM, RNA extraction, TaqMan®, and microarray
Cryosection preparation of the L3 vertebral body, the LCMprocedure
and validation of cell enrichment, RNA extraction and ampliﬁcation,
TaqMan, and initial microarray analysis were performed as previously
described [6]. Brieﬂy, LCM was performed on 4–6 μm cryosections of
vertebrae from the ﬁrst ﬁve animals per treatment group per time
point to enrich for OB, LC, and OCy subpopulations for transcriptional
analyses using Affymetrix Rat 230_2microarrays. Presence and absence
of ﬂuorochrome labelingwas used to identify surfaces for enrichment of
OB and LC, respectively, and trabecular elements were microdissected
to enrich for OCy. Data from three OB samples and three OCy samples
(out of 300 total samples) were excluded from the microarray analysis
based on poor hybridization quality control parameters. Basic statistical
analyses were undertaken using the R statistical computing platform
(version 3.1.0) and Bioconductor packages (affy 1.42.3, EBarrays
2.28.0). The criterion used for ﬁltering and statistical signiﬁcance was
a q-value (q) ≤ 0.1. The raw CEL ﬁles and normalized intensity data
were deposited in GEO (GSE71306). TaqMan analysis of a panel of key
genes and genes not present on themicroarray (Supplemental Material
2)was used to conﬁrm changes observed at 50mg/kg in OCy at d8, 183,
and 309. The TaqMan protocol described in Nioi et al. [6] was used with
aminormodiﬁcation that changes in expressionwere normalized using
the average of the three housekeeping genes (B2m, Hprt1, Tbp).
2.5. Gene co-expression network and biological function analyses
Microarray and histomorphometry were performed at matching
time points in this study. The WGCNA R package (version 1.43) [15]
was used to perform weighted correlation signed network analysis
that identiﬁed modules of co-expressed genes related to bone
histomorphometric parameters. Co-expression networks were created
for each cell type. Genes signiﬁcantly altered with q ≤ 0.1 in at least
two conditions (i.e., time point and Scl-Ab dose) were included in
the network construction. Correlations between log-transformed
histomorphometry parameters and module eigen vectors with
p ≤ 1e−4 (Bonferroni correction for multiple testing used to set thresh-
old) were considered signiﬁcant. Each of the gene expression modules
was analyzed to identify enriched gene ontology (GO) biological pro-
cesses (BPs) using the GOStats R package (version 2.30.0). GO terms
with p ≤ 1e−5 (Bonferroni corrected) were used to suggest BPs related
to the observed expression changes for each module. Differentially
expressed genes (DEGs) for each unique combination of cell type,
time point, and dose were uploaded into Ingenuity Pathways Analysis
software (QIAGEN, Redwood City, CA) and analyzed using upstream
regulator analysis (URA) to provide additional insight into biological
function. URA integrates previously observed cause–effect relationships
reported in the literature to predict the upstream molecules that areconsistent with the observed downstream gene expression changes
[16]. Upstream regulators with p ≤ 5e−6 (Bonferroni corrected) and
Z-score ≥ 2, i.e., activated (or ≤−2, i.e., inhibited), were considered
signiﬁcant. Upstream regulators that met this criterion at two or more
occurrences within a cell type were prioritized for further interpreta-
tion. Signiﬁcance criteria were stringent for URA in order to focus
on the most signiﬁcantly regulated signaling pathways. Complete URA
data are provided in Supplemental Material 3.
3. Results
3.1. Effects of Scl-Ab on bone formation, resorption, and mass
Scl-Ab resulted in transient dose-dependent increases in BFR/BS. At
3 mg/kg, BFR/BS was maximal at d29, returning to VEH by d85 where
it remained through d267 (Fig. 1A). At 50 mg/kg, BFR/BS was increased
at d8, peaked at d29, and decreased to VEH by d183. During the TFP,
there was a transient and near-total suppression of BFR/BS at d237,
followed by its recovery to VEH levels by d309. Ob.S/BSwas signiﬁcantly
increased at d8 at 3 mg/kg then decreased to VEH by d29. At 50 mg/kg,
Ob.S/BSwas signiﬁcantly increased d8 through d85, peaked at d29, then
decreased to VEH at d183 (Fig. 1B). During TFP, Ob.S/BSwas signiﬁcantly
decreased at the ﬁrst recovery time points for the 3 and 50 mg/kg
groups. Bone resorption (osteoclastic surface/bone surface; Oc.S/BS)
was generally dose-dependently decreased compared with VEH from
d29 to 183. Oc.S/BS was signiﬁcantly increased at 50 mg/kg during the
TFP time points of d237 and 309, coinciding with the expected reversal
of accrued bone mass secondary to drug clearance (Fig. 1C).
Dose-dependent increases in vertebral trabecular volumetric bone
mineral density (vBMD) by pQCT and cancellous bone volume/total vol-
ume (BV/TV) by histomorphometrywere observed in the Scl-Ab groups
(Fig. 1D, E). At 3 mg/kg, vBMD and BV/TV attained maximal values by
d29 that were sustained through d183, and then progressively de-
creased during the TFP to VEH at d267. At 50 mg/kg, vBMD and BV/TV
progressively increased to d183, and then decreased during the TFP
but remained signiﬁcantly increased at d309 compared with VEH
reﬂecting an incomplete reversal of accrued bone mass within the
observed time period.
3.2. Effects of Scl-Ab on total number of osteoblasts and osteoprogenitor
subpopulations
In Scl-Ab-treated rats, Ob.N was signiﬁcantly increased dose-
dependently at d8 and 29 and by d183 was similar to VEH. Ob.N
increased at the end of the TFP at 3 mg/kg corresponding to a slight in-
crease in BFR/BS and restoration of coupled bone remodeling. PTb.OP
number was decreased signiﬁcantly at d29 and at d183, approached
VEH at 3 mg/kg but was further decreased at 50 mg/kg. Values were
similar to VEH at the end of the TFP. A similar pattern of changes was
observed for Ma.OP number (Fig. 2).
3.3. OB lineage cell types exhibit distinct temporal gene expression patterns
that correlate with observed bone phenotypes
Co-expression analysis of DEGs (Supplemental Material 4) across
the time course deﬁned distinct time-dependent patterns that differed
within and between cell types. In OB, 1650 genes clustered into seven
modules (Fig. 3A), in LC, 291 genes clustered into three modules
(Fig. 3B), and in OCy, 1839 genes clustered into six modules (Fig. 3C).
One module per cell type was considered undeﬁned (module 0 in
each analysis) and was not shown or analyzed further. Modules were
named according to their cell type and rank-ordered by the number of
genes they contained (e.g., OB-1 was the OB module with the most
genes). The summarized view of the temporal gene expression patterns
observed in each cell type at 50mg/kg is shown in Fig. 3D.Of the 13 total
gene expressionmodules deﬁned by themicroarray analysis, only OB-4,
Fig. 1. Effect of Scl-Ab treatment on vertebral histomorphometric parameters. (A) BFR/BS. (B) Ob.S/BS. (C) Oc.S/BS. (D) Trabecular volumetric BMD. (E) BV/TV. Data are mean± standard
error of mean. *p ≤ 0.05. Vertical dotted line separates dosing phase on the left and TFP on the right.
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the bone histomorphometric parameters (Table 1). OB-5 and OCy-5,
modules enriched for genes related to extracellular matrix (ECM),
were positively correlated to Ob.S/BS and BFR/BS. OB-4, LC-2, and
OCy-1 were positively correlated to BV/TV, containing genes related to
ECM processing, cytoskeleton, and regulators of TGF-β, IGF, BMP, and
Hippo signaling, respectively. OCy-3 enriched for genes related to mito-
sis and cell cycle progression was negatively correlated to BV/TV. No
signiﬁcant correlations were observed with Oc.S/BS. The correlationFig. 2. Effect of Scl-Ab treatment on osteoblast lineage cell counts. (A) Ob.N. (B) PTb.OP number.
separates dosing phase on the left and TFP on the right.coefﬁcients for the individual genes within these OB and OCy modules
to BFR/BS and BV/TV are shown in Fig. 4.
3.4. Changes observed in genes related to Wnt signaling, extracellular
matrix, cell cycle arrest, and B-cell development
Similar to our previous assessment of the transcriptional response to
a single 100mg/kg dose of Scl-Abwithin the ﬁrst week of treatment [6],
Wnt signaling and Wnt target, ECM, cell cycle, and B-cell development(C)Ma.OP number. Data aremean± standard error of mean. *p ≤ 0.05. Vertical dotted line
Fig. 3.Time-dependent gene expression patterns in thedifferentOB lineage cell types at 50mg/kg Scl-Ab. (A) Heatmap of genes altered inOB. (B)Heatmapof genes altered in LC. (C)Heat
map of genes altered in OCy. Columns represent individual animals and rows represent speciﬁc genes. Each cell contains color-coded log2 ratios (treated animal/time-matched VEH group
mean). Red=upregulated, green=downregulated. (D) Average change in gene expression of treated animals over each of the gene co-expressionmodules identiﬁed in OB, LC, and OCy.
The horizontal line denotes average expression in VEH controls.
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signiﬁcant DEGs at 50 mg/kg mostly occurring in OCy.
Changes in Wnt signaling genes were limited to upregulation of
the noncanonical Wnt Wnt5b and the extracellular inhibitor Sfrp4,
both negative regulators of the canonical Wnt pathway in OCy at
≥d29. A limited number of canonical Wnt target genes were differen-
tially expressed across the time course. Amongst a master list of 106
genes described by the Nusse laboratory [17], 25 Wnt targets were sig-
niﬁcantly regulated in at least two occurrences, with OCy at 50 mg/kg
displaying themost consistent temporal patterns (Figs. 5A, 6A). The pat-
tern of Wnt target gene expression was similar in all three cell types atd8 including upregulation of Twist1 and Wisp1. However on d29, the
pattern of Wnt target genes expression changed in OCy with Twist1
returning to VEH level and upregulation of a different set ofWnt targets
(e.g., Cd44, Id2, Irx3, Vegfa) that remained elevated through treatment
(OCy-1). This included Tcf4 (Tcf7l2), a negative regulator of Wnt signal-
ing. Interestingly, signiﬁcant regulation of classic negative regulators of
the canonical Wnt pathway, such as Axin2 or Apcdd1, was not observed
in any of the subpopulations. Wisp1 was unique, with signiﬁcant
increases at d8 that persisted through d237 (OCy-1). Wnt targets with
decreased expression beginning on d29 included Birc5 (Survivin)
(OCy-3), Ccnd1, and Mmp9 (OCy-4). Only Enpp2 (OCy-2) displayed
Table 1
Gene co-expression analysis of OB, LC, and OCy identiﬁes gene modules correlated to histomorphometric parameters. Correlation coefﬁcients and p-values are shown for modules corre-
lated to one or more phenotypic parameters. Statistically signiﬁcant correlations (p ≤ 1e‐04) are highlighted in bold.
Phenotype OB-4 OB-5 LC-2 OCy-1 OCy-3 OCy-5
BFR/BS
0.11
(3e−01)
0.49
(3e−07)
−0.08
(4e−01)
−0.12
(3e−01)
0.19
(6e−02)
0.49
(3e−07)
Ob.S/BS
0.07
(5e−01)
0.72
(8e−17)
−0.14
(2e−01)
0.08
(4e−01)
0.01
(9e−01)
0.75
(9e−19)
Trabecular vBMD
0.59
(2e−10)
0.12
(3e−01)
0.49
(2e−07)
0.49
(3e−07)
−0.5
(1e−07)
−0.04
(7e−01)
BV/TV
0.64
(1e−12)
0.19
(7e−02)
0.51
(6e−08)
0.65
(6e−13)
−0.56
(2e−09)
−0.04
(7e−01)
153S. Taylor et al. / Bone 84 (2016) 148–159upregulation limited to the later dosing phase. Fewer regulated Wnt
target genes were present in the OB and LC at 50 mg/kg with Bglap
and Twist1 clustered in OB-5; Maea, Lbh, and Birc5 clustered in OB-1;
and Vegfc clustered in LC-1 (Fig. 5A).
Based on GO (GO:0000278, “mitotic cell cycle”), Scl-Ab regulated
183 genes related to cell cycle activity (Figs. 5B, 6B). Somewhat surpris-
ingly, the majority of cell-cycle-related DEGs were observed in the OCy
population, at the 50mg/kg dose level. Like theWnt target genes, regu-
lation ofmany of these genes beganond29. Genes that increased on d29
and sustained into the TFP included p53 target genes Cdkn1a (p21) and
Mdm2, and the tumor suppressor Lats2 (Hippo pathway). Genes that
decreased beginning on d29 and into the TFP included many p53 target
genes involved inmitosis and cell cycle progression (e.g., several cyclins
and cell division cycle proteins, Aurka, Bub1b, Chek1, Kif23, Kifc1, Knstrn,
Plk1) and the pro-mitotic transcription factor Foxm1.
DEGs related to ECM and B-cell development and the transcriptional
response to treatment with 3 mg/kg of Scl-Ab are presented in Supple-
mental Material 1.
3.5. Altered gene expression related to extracellular Wnt inhibitors as
detected by TaqMan
TaqMan analysis of a panel of select DEGs was used to conﬁrm
changes observed with 50 mg/kg Scl-Ab in OCy on d8, 183, and 309.
In general, excellent agreement was observed between the microarray
and TaqMan measurements (Suppl Fig. 7). However, Sostwas found to
be signiﬁcantly upregulated in OCy by TaqMan (+19-fold at d183,
Fig. 7A), but not by microarray. In addition, Dkk1, a Wnt inhibitor
not on the microarray, was increased in OCy by TaqMan (+9-fold at
d183). Other genes primarily expressed in OCy, including Dmp1 andFig. 4.Gene co-expressionmodules signiﬁcantly correlatedwith histomorphometry parameter
course are depicted for (A) OB and (B) OCy. Each symbol denotes a gene from a selected bioloMepe, were highly upregulated at d183 (+10-fold and 7-fold, respec-
tively). During the TFP, these OCy genes declined as BV/TVwas reduced.
3.6. Alteration in classical regulators of osteoclastogenesis by TaqMan
CSF1, TNFRSF11B (OPG), and TNFSF11 (RANKL) thatwere not signif-
icantly transcriptionally regulated by microarray were also assessed by
TaqMan. In OCy, CSF1 decreased during dosing (Fig. 7B) while OPG was
generally upregulated, and RANKL remained unchanged (Fig. 7C). The
resulting RANKL to OPG ratio was decreased through dosing in OCy
(Fig. 7C). During the TFP, many of the gene changes were consistent
with the observed increase in Oc.S/BS. Other genes that may have con-
tributed to the regulation of bone resorption included Wisp1, which
has been reported to be a negative regulator of osteoclastogenesis
[18]. Regulation of these geneswithin theOCy is consistentwith the rec-
ognized role of the OCy in regulation of bone resorption [19]. Together
with the microarray results, the expression pattern of these genes was
consistent with the suppression of bone resorption during dosing,
followed by an elevation during the TFP.
3.7. Upstream regulator analysis
URA was used to provide insight into the biological function associ-
ated with observed DEGs in OB, LC, and OCy, with the most consistent
patterns observed in OCy. Based on the statistical criterion used for
ﬁltering, several biological themes emerged.
Accompanying the early increase in BFR/BS at d8, there was signiﬁ-
cant predicted transient activation of c-Myc (MYC, Z-score = +4.6)
and Mycn (MYCN, Z-score = +3.6) signaling in OB. At d29, the time
point of maximal BFR/BS, coincident with changes in the expressions. Regression values from correlations between genes and BFR/BS or BV/TV across the time
gical class.
Fig. 5. Time-dependent gene expression patterns in the different OB lineage cell types at 50 mg/kg Scl-Ab. (A) Canonical Wnt target genes (Nusse list). (B) Mitotic cell cycle genes
(GO:0000278). Columns represent groups of biological replicates at each time point and rows represent speciﬁc genes (~35% of genes labeled in panel B). Each cell contains color-
coded log2 ratios (treated group mean/time-matched VEH group mean).
154 S. Taylor et al. / Bone 84 (2016) 148–159pattern ofWnt target genes, there was activation of signaling pathways
in OCy that would inhibit cell cycle progression (Fig. 8A). Of these, TP53
(p53), CDKN1A (p21), CDKN2A, RB1 (Rb), and Let-7 were amongst the
most consistently regulated, with p53 being themost statistically signif-
icant prediction in the entire dataset. Activation of p53 signaling was
also predicted in OB and LC at isolated time points during the treatment
phase. In conjunctionwith the activation of these pathways, therewas a
predicted suppression of pro-mitogenic pathways in OCy that included
c-Myc, E2F1, and FOXM1. These collective changes were sustained
through the dosing phase as BFR/BS declined (Fig. 8B). During the TFP,
transcription factor signaling trended toward control values as BV/TV
declined.
DEGs contributing to the prediction for activation of p53 signaling
were recognized as direct downstream p53 targets or were linked
to p53 signaling. These included many of the regulated genes related
to mitosis and cell cycle progression in module OCy-1 (e.g., tumor
suppressors Ndrg1, Ndrg2, and p21) and OCy-3 (e.g., Aspm, Bub1,Fig. 6. Changes in genes after treatmentwith Scl-Ab at 50mg/kg. Scl-Ab activated the expression
shown as percentage changewith Scl-Ab relative to the VEH groupmean for each time point. Da
on the left and TFP on the right.Ccnb1, Ccnb2, Kif23,Mcm3, Prc1, Racgap1, and Top2a) [20–23]. Many of
these p53 genes also contributed to the predicted activation of other
regulated pathways, though some DEGs were uniquely related to each
pathway. For CDKN2A, unique DEGs included upregulation (OCy-1) of
Cited2, a transcriptional regulator of the INK family of suppressors. For
RB1, unique DEGs included downregulation of Blm, Chaf1, and Lig1
(OCy-3) and upregulation ofMef2c (OCy-1) [24]. For the p21 pathway,
p21 itself was transcriptionally upregulated. For Let-7, a miRNA recog-
nized to regulate cell cycle and differentiation [25], unique DEGs
contributing to the activation score included downregulation of cell
division cycle-associated proteins (e.g., Cdca2, Cdca8) (OCy-3). Of the
pro-mitogenic pathways inhibited at the same time point, c-Myc signal-
ing was the most signiﬁcantly affected pathway. A large number
of DEGs contributed to the c-Myc activation status, notable were DEGs
in OCy reported as direct or downstream targets of c-Myc including
several cyclins (e.g., Ccnb1, Ccnb2, Ccne1) (OCy-3). Of the DEGs not
shared with c-Myc, inhibition of E2F1 signaling was associated withof genes involved in (A) canonicalWnt target activation, (B)mitotic cell cycle. Each gene is
ta aremean± standard error of mean. *q ≤ 0.1. Vertical dotted line separates dosing phase
Fig. 7. TaqMan analysis of OCy samples at d8, 183, and 309 highlights gene expression changes related toWnt inhibition and osteoclastogenesis. (A) Changes in expression represented as
% VEH group mean measured by TaqMan for Sost, Dkk1, and osteoclastogenesis genes related to (B) Csf and (C) RANKL/OPG. Data are mean ± standard error of mean. *p ≤ 0.05. Vertical
dotted line separates dosing phase on the left and TFP on the right.
155S. Taylor et al. / Bone 84 (2016) 148–159downregulation of known E2F1 target genes (Dut, E2f4, Hmgb2, and
Rfc2) (OCy-3) [26]. Unique DEGs suggesting inhibition of FOXM1 in-
cluded downregulation of Foxm1 itself (OCy-3).
Other major biological themes that emerged from the URA and met
statistical cutoff value in the OCy at 50 mg/kg included activation of
TGFB1 (TGF-β) signaling and inhibition of TBX2 signaling, inhibition of
granulocyte-macrophage colony-stimulating factor (CSF2) [27], activa-
tion of cell survival (NUPR1), angiogenesis (HIF1A), and anti-apoptotic
pathways (BNIP3L, NRAS), and inhibition of prostaglandin signalingFig. 8. Time-dependent changes in signaling pathways related to cell cycle progression and m
osteoblast lineage cell types at 50 mg/kg Scl-Ab. (A) Heat map of activation Z-scores for all mo
more time points. (B) Line plots of Z-scores in OCy for speciﬁc signaling pathways that are p
temporal changes in vertebral BFR/BS in black.(PTGER2), a major pathway involved in mechanotransduction [28]
(Fig. 8A). In OB and LC, signiﬁcant URA signaling was limited to activa-
tion of PRL, GATA1, and ERG signaling. At 3 mg/kg, none of these up-
stream regulators achieved statistical signiﬁcance.
4. Discussion
This study provides insights into the time-dependent changes in
vertebral bone formation and resorption, OB and OP numbers, anditogenesis that are predicted to be activated or inhibited, respectively, in the different
lecules in OCy that are predicted to be activated (purple) or inhibited (yellow) at two or
romitogenic, known tumor suppressors, or cell cycle progression inhibitors. Line plot of
156 S. Taylor et al. / Bone 84 (2016) 148–159transcriptional signaling in the OB lineage that occur in response to Scl-
Ab treatment in vivo for 6 months and a TFP. Analyses revealed a
marked and transient increase in bone formation and OB number
early in the treatment period that decreased progressively with contin-
ued administration of Scl-Ab. At the time of peak bone formation rate,
there were simultaneous reductions in progenitor populations that
were sustained throughout the remainder of the treatment period.
Coincident with the reduction in progenitor numbers, distinct changes
in the expression of canonical Wnt target and cell cycle genes occurred
with regulation of signaling pathways related to suppression of
mitogenesis and cell cycle progression, TGF-β, cell survival, angiogene-
sis, and mechanotransduction. Bone resorption was decreased during
treatment then increased in the TFP associated with resorption of
accrued bone mass. Expression pattern of genes with a major role in
regulation of osteoclastogenesis mirrored changes in bone resorption.
Similar to previously reported acute transcriptional changes in re-
sponse to Scl-Ab [6], changes in DEGs at d8 were similar in OB, LC, and
OCy with increased expression of a limited number of known canonical
Wnt target genes, led byWisp1 and Twist1, and increased expression of
numerous ECM genes (Fig. 9). Associated with these changes were
dose-dependent increases in bone formation and OB numbers without
signiﬁcant changes in OP numbers. The initial dramatic increase in OB
number is likely due to activation of LC; however, proliferation and
recruitment of progenitors may contribute. URA revealed transient
stimulatory signals for mitogenesis with predicted activation of c-Myc
and n-Myc signaling in OB at d8. The upregulation of Twist1 in all
subpopulations may serve to limit the initial stimulatory response toFig. 9. Potential mechanism of action of Scl-Ab with acute and chronic administration. DEGs (o
enriched laser capture microdissection samples from ovariectomized rat vertebra treated
Associations between genes that were increased (red) or decreased (green) are illustrated. Pa
Within the ﬁrst week of treatment, Scl-Ab activated canonical Wnt signaling, activating a deﬁn
decreased bone resorption. With extended treatment, the nature of Wnt signaling changed,
Wnt inhibitor synthesis, resulting in attenuation of the bone-forming response.Scl-Ab as Twist1 has been demonstrated to inhibit osteoblast differenti-
ation [29]. Signaling by c-Myc in OB is surprising as it is a terminally dif-
ferentiated cell, however, c-Myc expression has been linked to cellular
hypertrophy and increased protein synthesis, independent of cell cycle
effects [30]. It cannot be excluded that OB-enriched samples likely
contained Ptb.OP due to their close location in the vascular canopy
over osteoblastic surfaces and the width of tissue captured from the
bone surface (30 μm) [6].
At the time of peak BFR/BS on d29, a pronounced shift in transcrip-
tional signaling occurred in the OCy coincident with signiﬁcant
decreases in OP numbers. The nature of Wnt signaling changed at d29
with Twist1 expression returning to baseline, sustained upregulation
of Wisp1 and upregulation of several different Wnt target genes that
decreased at different rates in the TFP. In addition to Wnt signaling
changes, there was rapid regulation of other DEGs and signaling
pathways that integrate and/or negatively regulate canonical Wnt
signaling. These included the Hippo (increased Lats2), noncanonical
Wnt (increased Wnt5b), and TGF-β pathways. The canonical Wnt
pathway is known to form a signaling network with other pathways,
notably TGF-β and Hippo pathways, to modify the biological output of
the pathway [31] and Wnt5b has been shown to inhibit canonical
Wnt signaling [32].
However, themost signiﬁcantly regulated pathways inOCy based on
URA analysis started at d29 and were related to inhibition of cell cycle
progression and mitogenesis with p53 and c-Myc signaling being the
most signiﬁcantly regulated pathways. These signaling changes were
generally sustained through treatment and often into the TFP. A centralvals), upstream regulators (rectangles), and histomorphometry data from the osteocyte-
with Scl-Ab for up to 183 days were incorporated into a hypothetical gene network.
thways that have been reported to respond to skeletal loading are annotated with a star.
ed set of Wnt target genes that have been associated with increased bone formation and
likely driven by increased p53 (and decreased c-Myc) signaling as well as by increased
157S. Taylor et al. / Bone 84 (2016) 148–159role for c-Myc signaling in response to Scl-Ab is consistent with its
role as a known Wnt target gene [33], with the expected upregulation
of c-Myc signaling observed acutely in OB. Thereafter, c-Myc inhibition
in theOCy fromd29 through the TFP underscored themodulation of the
functional output of canonicalWnt signaling over time. Induction of p53
signaling and secondary tumor suppressor pathways by canonical Wnt
signaling has long been recognized in tumor biology with a key role for
Cdkn2a, the gene for the INK4a/Arf locus that encodes both p16INK4a and
p19ARF (p14ARF in humans). p14ARF is activated by hyperproliferative
signals including c-Myc. A consequence of p14ARF activation (Cdkn2a
signaling; observed in this study) is inhibition of Mdm2, resulting in
stabilization of p53. Activation of p53 signaling and upregulation of
its downstream target p21 inhibits phosphorylation of Rb, resulting in
activation of Rb signaling [34]. Transcriptional changes observed in the
current dataset that could further enhance CDKN2A signaling are the
downregulation of Twist1, potentially mediated by p53 [35], inhibition
of TBX2 signaling through activation of TGF-β signaling [36,37], and up-
regulation of DMP [38]. Enhanced p53 signaling could further feedback
to suppress Wnt signaling via mechanisms including miRNAs and up-
regulation of Dkk1, which was signiﬁcantly upregulated in the current
study [39–41]. The acute activation of canonical Wnt signaling leading
to subsequent activation of the INK4a/Arf locus and induction of these
major tumor suppressor pathways would contribute to the reduction
in OP numbers and subsequent self-regulation of bone formation
observed with Scl-Ab (Fig. 9).
Many studies provide strong evidence for central roles of p53 and
Rb in the regulation of osteoblastogenesis including loss-of-function
and gain-of-function studies. p53(−/−) mice have high bone mass
and enhanced proliferation and differentiation of OPs. In mice with a
conditional deletion ofMdm2, OPs have elevated levels of p53, reduced
proliferation, and reduced expression of Runx2 and osteocalcin [42]. Rb
has been reported to regulate OB differentiation by inhibition of E2F and
promotion of cell cycle exit [43]. The importance of a functional Cdnk2a
locus in the control of c-Myc signaling and regulation of OP proliferation
is supported by osteosarcoma induction in INK4a/Arf (−/−) stromal
cells overexpressing c-Myc [44]. The linking of these suppressor path-
ways downstream of activated canonical Wnt signaling through
Cdnk2a would be one mechanism to tightly control, both temporally
and spatially, the proliferative effects of canonical Wnt signaling.
Robust induction of cell cycle inhibitory pathways with coincident
suppression ofmitogenic pathwayswould be a transcriptional response
not unexpected in cells of the OB lineage with proliferative capacity,
such as the progenitor pools, where cell cycle arrest could ultimately
lead to decreased BFR/BS. However, these signals were observed in
the OCy, a terminally differentiated cell encased in bone matrix. This is
an unexpected ﬁnding with unclear functional consequences. The OCy
has been shown to be important in regulating bone formation and
resorption [19], as well as in mediating the bone anabolic response to
activated canonical Wnt signaling [45]. It is also the primary bone cell
retaining active Wnt signaling in the adult skeleton [46]. The OCy is
poised to communicate with cells on the bone surface and in the mar-
row through its extensive dendritic network. The OCy has been shown
to regulate hematopoiesis and progenitor mobilization, underscoring
its ability to regulate marrow cell populations [47,48]. Thus, signals in
the OCy could potentially modulate OP activity in the marrow. This
could be affected by OCy-derived secreted factors, and/or by transfer
of OCy-derived exosomes, or microvesicles to target cells. OCy-derived
matrix vesicles have recently been shown to modulate OB function
[49]. The OCy has also been shown to display transcriptional plasticity,
adopting transcription patterns that resemble the OB or osteoclast
depending on the condition [6,50]. An alternative hypothesis is that, in
response to canonical Wnt signaling, OCy assumes the transcriptional
response of an OP. This response could theoretically represent a vestige
of theOCyprogenitor origins, or perhaps an indication of changes occur-
ring in the actual progenitor population. Unfortunately, rat OPs could
not be harvested with currently available techniques because robustphenotypic markers are not available in the rat, and RNA quality
may not be preserved during immunohistochemical staining for LCM.
Additional studies are required to characterize the transcriptional sig-
naling occurring in the OP populations with Scl-Ab and to determine if
the reduction observed in OP populations correlates with regulation of
pathways that limit cell cycle progression.
The progressive increase in BV/TV may have also served to provide
negative feedback to signaling pathways by decreasing tissue-level
stress, as suggested by the strong association between BV/TV and gene
co-expression modules that reﬂect decreased cell cycle activity in OCy.
OCy are thought to play a central role in the response of bone to altered
loading conditions. Many hypotheses exist on howOCy transduce these
signals and regulate bone formation, including a potential role of p53.
Upon tail suspension, wild-type mice exhibited increased p53 and
p21 expression in bone marrow cells from the unloaded hind limbs,
consistent with a decrease in BFR/BS in vivo and colony-forming units
in vitro [51]. In contrast, p53(−/−) mice were protected from the tail
suspension-mediated decrease in BFR/BS and colony-forming units. In
addition, sclerostin is a known mechanoresponsive gene, with tail
suspension resulting in an increase in Sost expression [52]. The inhi-
bition of Ptger2 signaling in the OCy may have also contributed to
a negative feedback to inactivate signaling consistent with the
mechanostat hypothesis [53]. Thus, the increases in bone mass may
provide an important feedback mechanism that signals through
p53 and Wnt to prevent further bone-forming effects with long-
term Scl-Ab administration.
The time required for BFR/BS to return to control levels was dose
dependent, with more rapid self-regulation at 3 mg/kg. The number,
magnitude, and duration of regulation of DEGs showed similar dose de-
pendency, suggesting the regulatory responses induced with long-term
Scl-Ab treatment titrate to control dose-dependent effects on BFR/BS.
Transcriptional changes of genes important in the regulation of oste-
oclastogenesis mirrored changes in bone resorption. As a known Wnt
target gene, the regulation ofOpg andOpg:RANKL ratio by Scl-Ab is con-
sistent with previous in vitro data [54]. Csf1, a factor essential for osteo-
clast differentiation and survival and a gene suppressed by p53
signaling, was also signiﬁcantly regulated [55,56].Wisp1, recently dem-
onstrated to be a positive regulator of bone formation and a negative
regulator of bone resorption [18],was regulated in concertwith changes
in bone resorption. As Csf2 has been demonstrated to promote osteo-
clastogenesis, inhibition of Csf2 signaling detected by URA would also
limit bone resorption [57]. These data suggest that the inhibition of
bone resorption in response to Scl-Ab likely involves multiple signaling
pathways.
In conclusion, vertebrae from aged OVX rats treated with Scl-Ab for
6 months followed by a TFP displayed a rapid and marked increase in
BFR/BS and Ob.N with maximal BFR/BS at d29, followed by a progressive
decline with continued dosing through d183. During the TFP, BFR/BSwas
initially suppressed and then returned to VEH levels. Trabecular bone
mass progressively increased through d183, and declined during the
TFP. Oc.S/BS decreased during dosing and increased in the TFPwith corre-
sponding changes in expression ofmajor regulators of osteoclastogenesis.
Reduction in osteoprogenitors preceded the reduction in OB number
and bone formation and correlatedwith signiﬁcant transcriptional chang-
es in OCy. Changes included induction of signaling pathways known to
regulate Wnt signaling and suppress mitogenesis and cell cycle progres-
sion. The temporal correspondence of these changes suggests that this
coordinated response of downstream regulatory pathways modulates
the transcriptional output of canonical Wnt signaling and contributes to
self-regulation of bone formation with long-term Scl-Ab treatment.
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